Aerie Pharmaceuticals IPO Research Information

Aerie Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Aerie Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Aerie Pharmaceuticals	AERI - NASDAQ	$12.00-$14.00	$10.00	$10.55	6.72 million	10/25/2013
Underwriter(s): RBC Capital Markets, Stifel Nicolaus Weisel
Co-Manager(s): Lazard Capital Markets, Canaccord Genuity
Industry: Health Care
Filing(s): Filed 2013-09-17

Aerie Pharmaceuticals Quote & Chart - Click for current quote - AERI

About Aerie Pharmaceuticals (adapted from Aerie Pharmaceuticals prospectus):
They are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AERI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.